ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Valsartan

Also written as “valsartan”, “sacubitril/valsartan” and “valsartan plus hydrochlorothiazide”.

Its studies are mostly in Hypertension · Essential Hypertension · Heart Failure · Diabetes Mellitus, Type 2 · Proteinuria, led by 14 companies.

Drug pageValsartan: every studyMany companies study it; this page follows only the 125 they lead. All 254 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 10, 2005125 company-led studies, 1 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartisits history only1060 open or runningphase 4since Sep 10, 2005Nov 30, 2004none ahead
LG Chem50 open or runningphase 3since Aug 5, 2013May 11, 2010none ahead
IlDong Pharmaceuticalits history only20 open or runningphase 3since May 20, 2014May 20, 2014none ahead
Sun Pharmaceutical Industriesits history only20 open or runningno phasesince Jul 21, 2014Jul 21, 2014none ahead
ARKAY Therapeuticsits history only10 open or runningphase 2since Sep 23, 2018Sep 23, 2018none ahead
Dexa Medica Groupits history only10 open or runningno phasesince Aug 3, 2015Aug 3, 2015none ahead
EMSits history only10 open or runningphase 3since Nov 23, 2015Nov 23, 2015none ahead
Farma de Colombiaits history only10 open or runningphase 3since May 7, 2013May 7, 2013none ahead
Genuine Research Center, Egyptits history only10 open or runningphase 1since Jul 30, 2015Jul 30, 2015none ahead
Hanlim Pharm.its history only10 open or runningphase 1since Aug 2, 2018Aug 2, 2018none ahead

Also a collaborator on its studies: Bristol-Myers Squibb, GlaxoSmithKline and Bayer.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of LG Chem only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 11, 2010First study: phase 2 study in Essential HypertensionFirst studyNCT01122251 · 441 enrolled · Korea, Republic of
  2. Aug 5, 2013Phase 1 study in HypertensionNCT01918358 · 60 enrolled · Korea, Republic of
  3. Aug 5, 20132 phase 3 studies in HypertensionNCT01918332, NCT01928628
  4. May 8, 2018Phase 1 study in Healthy Male VolunteersNCT03532854 · 42 enrolled · Korea, Republic of

TargetBeta

AGTR1 →read by rule
“Type-1 angiotensin II receptor antagonist”ChEMBL 37, by rule

Other programs on AGTR1

ProgramCompanyFurthest phaseStudies
TelmisartanruleBoehringer Ingelheimphase 4132
LosartanruleOrganonphase 458
azilsartan medoxomilruleTakedaphase 425
sparsentanruletravere-therapeutics-incphase 49

Studies

All 5 LG Chem leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03532854Healthy Male Volunteers · Korea, Republic of1CompletedAug 25, 201842
NCT01928628Hypertension · Korea, Republic of3CompletedApr 2013449
NCT01918358Hypertension · Korea, Republic of1CompletedJan 201360
NCT01918332Hypertension · Korea, Republic of3CompletedMar 2013168
NCT01122251Essential Hypertension · Korea, Republic of2CompletedMay 2010441

How it is read

Names in the registry

  • “Valsartan”, 31 entries
  • “valsartan”, 23 entries
  • “sacubitril/valsartan”, 5 entries
  • “valsartan plus hydrochlorothiazide”, 5 entries
  • “valsartan + amlodipine”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.